TVGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TV

Mkt Cap

$45.0M

Volume

2.28K

Next Earnings

November 13th

Loading chart

TV

TVGNTevogen Inc. Common Stock

TVGN

Pay with—

Available Balance0.00

TV

Mkt Cap

$46.1M

Volume

2.28K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Tevogen Bio Announces 2026 Annual Meeting of StockholdersTevogen Bio Holdings Inc. (NASDAQ: TVGN) announced its 2026 Annual Meeting of Stockholders scheduled for August 24, 2026, to be held virtually. The company has set July 23, 2026 as the record date for stockholders and the deadline for submitting stockholder proposals and director nominations. Tevogen continues to focus on its three complementary initiatives: Tevogen Bio (biotechnology), Tevogen.AI (artificial intelligence and technology), and Tevogen Healthcare Services, aimed at improving affordability and accessibility of life-saving medicines.GlobeNewswire Inc. · Jul 14, 2026

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services OrganizationTevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring a Management Services Organization (MSO). If completed, the transaction could expand Tevogen's healthcare infrastructure and support its evolution into a revenue-generating enterprise with combined annual revenue of approximately $100 million, alongside its biotechnology and AI technology arms.Benzinga · May 21, 2026

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share UtilizationTevogen Bio Holdings Inc. announced capital discipline measures including its lead investor Dr. Manmohan Patel's commitment to maintain shareholdings, a pledge to limit share utilization to 1% of authorized shares over the next 12 months or until cash-flow positive, and evaluation of acquisitions that could generate over $50 million in combined annual revenue. The company is also exploring ways to better reflect the value of its assets and continues to evaluate a potential special cash dividend.GlobeNewswire Inc. · Mar 13, 2026

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care PlatformTevogen Bio Holdings Inc. (NASDAQ: TVGN) announced progress on TVGN 489, its investigational T-cell therapy for Long COVID, following the appointment of a new leadership team on March 9, 2026. The company expanded HLA target coverage to reach 65% of the U.S. population and is evaluating the acquisition of Sciometrix's Clinicus platform for real-world patient monitoring. Proof-of-concept data showed 100% of treated high-risk patients did not develop Long COVID.GlobeNewswire Inc. · Mar 11, 2026

Tevogen Bio Explores Buyout To Boost Generics PlatformTevogen Bio Holdings (NASDAQ:TVGN) announced a non-binding Letter of Intent to explore acquiring Apozeal Pharmaceutical Inc. to strengthen its generics platform and enhance pharmaceutical affordability. The stock surged to $10.8 before falling, and is now trading at a 52-week low of $6.56, down 15.41% on the day. The company also approved a 50-for-1 reverse stock split and is considering other life sciences transactions.Benzinga · Mar 6, 2026

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal PharmaceuticalTevogen Bio Holdings (NASDAQ: TVGN) announced a signed Letter of Intent to evaluate a potential acquisition of Apozeal Pharmaceutical, a company focused on cost-effective medicines. The acquisition would provide Tevogen with 11 FDA-approved generic drugs, multiple pending applications, and a development pipeline, supporting its Tevogen Generics initiative aimed at domestic pharmaceutical manufacturing and affordability. The transaction remains subject to due diligence and customary closing conditions.Benzinga · Mar 5, 2026

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal PharmaceuticalTevogen Bio Holdings Inc. (NASDAQ: TVGN) announced a non-binding Letter of Intent to evaluate the potential acquisition of Apozeal Pharmaceutical, a generics-focused pharmaceutical company. The deal would provide Tevogen with 11 FDA-approved generic drugs, multiple pending ANDAs, and a development pipeline, supporting its Tevogen Generics initiative aimed at domestic pharmaceutical manufacturing and affordability. The transaction remains subject to due diligence and definitive documentation.GlobeNewswire Inc. · Mar 5, 2026

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform ClinicusTevogen Bio Holdings (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring Sciometrix Inc., a healthcare technology company that develops the Clinicus digital care management platform. The potential transaction would result in Tevogen holding a majority voting interest in Sciometrix and aims to transform Tevogen into a revenue-generating healthcare enterprise by integrating digital care management capabilities with its Tevogen.AI initiative.Benzinga · Feb 26, 2026

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform ClinicusTevogen Bio Holdings (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring Sciometrix Inc., a healthcare technology company that develops the Clinicus digital care management platform. The potential transaction would result in Tevogen holding a majority voting interest in Sciometrix and aims to integrate digital care management capabilities with Tevogen.AI to create a revenue-generating healthcare enterprise combining biotech with healthcare services.Benzinga · Feb 26, 2026

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to ShareholdersTevogen Bio Holdings Inc. announced that its Board of Directors intends to evaluate a potential one-time special cash dividend to shareholders, contingent upon achieving specified financial milestones including revenue and earnings targets. The dividend would be subject to future financial performance, capital requirements, and solvency compliance, with no assurance of declaration or timing.GlobeNewswire Inc. · Jan 30, 2026

to start trading

TV

TVGNTevogen Inc. Common Stock

TVGN

Pay with—

Available Balance0.00

Your PositionYou don't own any TVGN yet.

Related Tickers

Earnings